Form 4: scPharmaceuticals Director Frederick Hudson Granted 30,000 Stock Options

scPharmaceuticals Inc. Director Frederick M. Hudson was granted 30,000 stock options with an exercise price of $3.85, aligning his interests with shareholder value.

Summary

• Frederick M. Hudson, a Director of scPharmaceuticals Inc. (SCPH), was granted 30,000 stock options on June 3, 2025.
• The stock options have an exercise price of $3.85 per share.
• These options will vest in full upon the earlier of June 3, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Mr. Hudson directly beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued commitment from a director and aligns their financial interests with shareholder value, which is generally viewed favorably.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the company's stock price increases above the exercise price.
• The long expiration date (June 3, 2035) provides a significant window for the options to become in-the-money, encouraging long-term strategic focus.

Future Outlook

The stock option grant, with its vesting schedule, indicates an expectation of continued service from the director and aims to incentivize long-term value creation for the company.

Management Comments

• The grant of stock options to Director Frederick M. Hudson is a standard component of executive and director compensation, designed to align their financial interests with the long-term performance of scPharmaceuticals Inc.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, as a means of non-cash compensation and incentive for long-term commitment and performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice in publicly traded companies, including those in the pharmaceutical industry, to align director incentives with shareholder returns.
• The exercise price of $3.85, being the market price at the time of grant (implied by a $0 price of derivative security), is typical for incentive stock options.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's financial incentives with the company's stock performance, potentially benefiting shareholders through increased long-term value creation.

Next Steps

• The stock options will vest upon the earlier of June 3, 2026, or the next annual meeting of scPharmaceuticals' stockholders.

Key Dates

Keywords

scPharmaceuticals, SCPH, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership